Transforming Surgery with Versius
Versius, the remarkable surgical robot, stands as the second most utilized soft tissue surgical robot worldwide. Recently, it has reached an impressive milestone, having been employed in over 30,000 surgical cases globally across various specialties such as urology, general surgery, gynecology, and thoracic surgery.
The Versatility of Versius
More than 70% of healthcare facilities that have adopted Versius are leveraging its capabilities across two or more specialties. This adaptation highlights the system's flexibility, allowing it to fit into diverse surgical environments and workflows seamlessly. Its modular design enables easy relocation across departments, making it an ideal choice in a variety of care settings.
Innovative Enhancements to Versius Plus
CMR Surgical has recently unveiled significant upgrades to Versius Plus, which include the integrated fluorescence imaging system, vLimeLite, and the Ultrasonic Dissector, an advanced energy instrument specifically designed for Versius. These enhancements are expected to broaden the adoption of robotic-assisted surgery even further, equipping surgeons with tools to tackle increasingly complex surgical procedures.
User Experience and Professional Insights
Massimiliano Colella, CEO of CMR Surgical, expressed pride in the milestone achieved by Versius. "Over 30,000 patients have benefited from Versius, underscoring our objective to revolutionize surgery for the better. This achievement is a tribute to the surgeons who embraced Versius to enhance patient care and to our dedicated team committed to providing exceptional experiences for our clients."
Expert Perspectives on Versius
Dr. Eric Potiron, a urologist from Clinique Urologique Nantes-Atlantis, shared his views on the system's effectiveness in his practice. He stated, "With Versius, I can perform complex cancer surgeries and high-volume urological procedures effectively. Its adaptability allows us to establish outpatient programs for radical prostatectomies, demonstrating its impact on patient care."
Clinical Evidence and Future Directions
Clinical research involving Versius has been highlighted in prestigious international medical journals such as the International Journal of Surgery and BJU International. Following critical product advancements and securing regulatory approvals, including FDA marketing authorization for cholecystectomy, CMR Surgical's focus is on expanding the accessibility of Versius in more hospitals and entering new markets.
About CMR Surgical
CMR Surgical is dedicated to transforming surgery with Versius, its next-generation robotic surgical system. Headquartered in Cambridge, United Kingdom, CMR aims to collaborate with surgical teams, hospitals, and healthcare providers to democratize robotic minimal access surgery while enhancing surgical care worldwide. Since its inception in 2014, CMR has established itself as a leading medical devices company, backed by a strong international shareholder base.
Frequently Asked Questions
What is Versius?
Versius is a robotic surgical system designed to assist surgeons in performing minimally invasive soft tissue surgeries more effectively and accurately.
How many surgical cases have been performed with Versius?
Over 30,000 surgical cases have been completed globally using the Versius surgical robot, highlighting its widespread adoption in the medical community.
What specialties utilize Versius?
Versius is used across various surgical specialties, including urology, general surgery, gynecology, and thoracic surgery.
What enhancements have been made to Versius Plus?
Recent upgrades to Versius Plus include the vLimeLite fluorescence imaging system and the Ultrasonic Dissector, both designed to enhance surgical capabilities.
What is CMR Surgical's mission?
CMR Surgical aims to transform the landscape of surgery by making robotic minimal access surgery accessible and affordable for patients around the world.
